Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Inclusion Criteria: * Histologically confirmed metastatic uveal melanoma in the liver * Tumor burden \< 75%. Patients must have at least one tumor measuring \>= 10 mm in longest diameter by magnetic resonance imaging (MRI) or triphasic computed tomography (CT) (if MRI is not available or contraindicated) * No prior transarterial catheter-directed therapies. Prior hepatic tumor ablation, hepatic radiation or liver resection will be permitted as long as growing measurable liver tumors exists. Prior systemic treatments are allowed as long as there are no outstanding toxicities greater than grade 1 * Willingness and ability to give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Serum creatinine =\< 2.0 mg/dl * Bilirubin =\< 2.0 mg/ml. Exceptions will be made for patients with diagnosed Gilbert's Syndrome. In this instance, a bilirubin level =\< 3.0 mg/ml will be allowed for this patients with this syndrome * Albumin \>= 3.0 g/dl * No ascites * Granulocyte count \>= 1500/m\^3 * Platelet count \>= 150,000/m\^3 Exclusion Criteria: * Less than 18 years of age * Previous liver-directed treatments including immunoembolization, chemoembolization, radioembolization, hepatic arterial perfusion, or drug-eluting beads * Presence of life-limiting extrahepatic metastasis that requires systemic treatment within 3 months. However, radiation treatment of extrahepatic metastases such as bone, lymph nodes or subcutaneous metastases will be permitted whi…